Hosted on MSN15h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
BioSpace22h
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
PMLiVE22h
Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients
Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...